Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc., 10534 [2019-05392]

Download as PDF amozie on DSK9F9SC42PROD with NOTICES 10534 Federal Register / Vol. 84, No. 55 / Thursday, March 21, 2019 / Notices file written submissions on the issues of remedy, the public interest, and bonding. Third-party submissions should be filed no later than the close of business on March 29, 2019. No further submissions on any of these issues will be permitted unless otherwise ordered by the Commission. Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit eight (8) true paper copies to the Office of the Secretary by noon the next day, pursuant to section 201.4(f) of the Commission’s Rule of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer to the investigation number (‘‘Inv. No. 337– TA–1076’’) in a prominent place on the cover page and/or first page. (See Handbook for Electronic Filing Procedures, https://www.usitc.gov/ documents/handbook_on_filing_ procedures.pdf). Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel[1] solely for cybersecurity purposes. All non-confidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS. The authority for the Commission’s determination is contained in Section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of 1 All contract personnel will sign appropriate nondisclosure agreements. VerDate Sep<11>2014 18:27 Mar 20, 2019 Jkt 247001 Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: March 15, 2019. Katherine Hiner, Acting Secretary to the Commission. [FR Doc. 2019–05353 Filed 3–20–19; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc. ACTION: JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES Meeting of the Advisory Committee; Meeting Joint Board for the Enrollment of Actuaries. ACTION: Notice of Federal Advisory Committee meeting. AGENCY: The Joint Board for the Enrollment of Actuaries gives notice of a closed meeting of the Advisory Committee on Actuarial Examinations. DATES: The meeting will be held on April 12, 2019, from 8:30 a.m. to 5:00 p.m. ADDRESSES: The meeting will be held at Willis Towers Watson, 500 N Akard Street, 41st Floor, Dallas, TX 75201. FOR FURTHER INFORMATION CONTACT: Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, at (202) 317– 3648. SUMMARY: Notice is hereby given that the Advisory Committee on Actuarial Examinations will meet at Willis Towers Watson, 500 N Akard Street, 41st Floor, Dallas, TX 75201, on April 12, 2019, from 8:30 a.m. to 5:00 p.m. The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial mathematics, pension law and methodology referred to in 29 U.S.C. 1242(a)(1)(B). A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the subject of the meeting falls within the exception to the open meeting requirement set forth in Title 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such meeting be closed to public participation. SUPPLEMENTARY INFORMATION: Dated: March 14, 2019. Thomas V. Curtin, Jr., Executive Director, Joint Board for the Enrollment of Actuaries. Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 20, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on Dec 12, 2018, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mailstop 514, Newark, Delaware 19702–2461 applied to be registered as a bulk manufacturer of the following basic class of controlled substance: SUPPLEMENTARY INFORMATION: Controlled substance Ecgonine ........................ Drug code 9180 Schedule II The company plans to produce the listed controlled substance in bulk to be used in the manufacture of DEA exempt products. Dated: March 6, 2019. John J. Martin, Assistant Administrator. [FR Doc. 2019–05402 Filed 3–20–19; 8:45 am] [FR Doc. 2019–05392 Filed 3–20–19; 8:45 am] BILLING CODE 4830–01–P BILLING CODE 4410–09–P PO 00000 Frm 00059 Fmt 4703 Sfmt 9990 E:\FR\FM\21MRN1.SGM 21MRN1

Agencies

[Federal Register Volume 84, Number 55 (Thursday, March 21, 2019)]
[Notices]
[Page 10534]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-05392]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Siemens 
Healthcare Diagnostics Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before May 20, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on Dec 
12, 2018, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mailstop 
514, Newark, Delaware 19702-2461 applied to be registered as a bulk 
manufacturer of the following basic class of controlled substance:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Ecgonine...............................     9180  II
------------------------------------------------------------------------

    The company plans to produce the listed controlled substance in 
bulk to be used in the manufacture of DEA exempt products.

    Dated: March 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-05392 Filed 3-20-19; 8:45 am]
 BILLING CODE 4410-09-P